Compare ALTO & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALTO | AKBA |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.7M | 248.3M |
| IPO Year | 2005 | 2014 |
| Metric | ALTO | AKBA |
|---|---|---|
| Price | $3.73 | $0.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $8.33 | $3.92 |
| AVG Volume (30 Days) | 901.9K | ★ 8.6M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 119.51 | 93.94 |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $917,927,000.00 | N/A |
| Revenue This Year | $5.33 | N/A |
| Revenue Next Year | $1.09 | N/A |
| P/E Ratio | $17.50 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.40 | $0.54 |
| 52 Week High | $6.11 | $1.89 |
| Indicator | ALTO | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 50.56 | 25.15 |
| Support Level | $3.46 | N/A |
| Resistance Level | $3.79 | $1.54 |
| Average True Range (ATR) | 0.15 | 0.07 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 44.66 | 9.73 |
Alto Ingredients Inc is a producer and distributor of specialty alcohols, renewable fuels and essential ingredients in the United States. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels. Its customers include food and beverage companies and consumer products manufacturers and distributors. The company operates under three segments: Marketing and distribution, Pekin Campus production, and Western production.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.